The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

CellFE, a leader in non-viral gene editing technology, today announced the launch of its highly anticipated CellFE T-Rest ("Resting T Cell Kit"), a first-in-class cell manufacturing transfection media ...

CellFE, a leader in non-viral gene editing technology, today announced the launch of its highly anticipated CellFE T-Rest ...

Metagenomi says it hopes to start clinical trials next year to test MGX-001, its gene-editing therapy candidate for ...

The Trump administration has a historic opportunity to secure the United States’ position as the 21st-century biopower.